The efficacy of adjuvant targeted therapy in ALK fusion and EGFR mutation NSCLC has been demonstrated, while the effectiveness of perioperative targeted therapy for BRAF V600E NSCLC remains uncertain. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.